A Single-dose Dose Escalation Trial in a Randomised, Single-blind, Placebo-controlled Group-comparison Design to Investigate the Safety and Tolerability of XEN-D0501 in 24 Patients With Diabetes Mellitus Type 2
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs XEN D0501 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors PILA PHARMA
- 10 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 10 Apr 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
- 07 Jun 2017 New trial record